For instance, treatment of SKGT4 esophageal cancer cell lines [29] and endometrial tumor cell lines (NUT12 and NUT81) [16], that show GPX3 promoter hypermethylation, with the demethylating agent 5-aza-2′-deoxycytidine (5Aza-dC) and the histone deacetylace inhibitor, trichostatin A (TSA) results in re-expression of GPX3 mRNA. This evidence concerns the gene GPX3 and endometrium neoplasm.